Terms: = Gastric cancer AND PDCD1, CD279, PD-1, PD1, SLEB2, hPD-1, hPD-l, hSLE1 AND Staging
5 results:
1. [Enhancing survival outcomes in stage Ⅲ gastric/esophagogastric junction cancer: a retrospective study of immune checkpoint inhibitors and adjuvant chemotherapy based on real-world data].
Yang XQ; Rao Z; Wei HK; Xue ZC; Liu HY; Duan QF; Sun XW; Wang W
Zhonghua Wei Chang Wai Ke Za Zhi; 2024 Apr; 27(4):395-402. PubMed ID: 38644245
[No Abstract] [Full Text] [Related]
2. Evaluation of ITGB1 expression as a predictor of the therapeutic effects of immune checkpoint inhibitors in gastric cancer.
Xu C; Xie XL; Kang N; Jiang HQ
BMC Gastroenterol; 2023 Sep; 23(1):298. PubMed ID: 37667169
[TBL] [Abstract] [Full Text] [Related]
3. [Safety and efficacy of laparoscopic surgery in locally advanced gastric cancer patients with neoadjuvant chemotherapy combined with immunotherapy].
Lv JB; Yin YP; Zhang P; Cai M; Chen JH; Li W; Li G; Wang Z; Wang GB; Tao KX
Zhonghua Wei Chang Wai Ke Za Zhi; 2023 Jan; 26(1):84-92. PubMed ID: 36650004
[No Abstract] [Full Text] [Related]
4. A cohort study using IL-6/Stat3 activity and pd-1/PD-L1 expression to predict five-year survival for patients after gastric cancer resection.
Li XN; Peng YH; Yue W; Tao L; Zhang WJ
PLoS One; 2022; 17(12):e0277908. PubMed ID: 36454780
[TBL] [Abstract] [Full Text] [Related]
5. A Four-Factor Immunoscore System That Predicts Clinical Outcome for Stage II/III gastric cancer.
Wen T; Wang Z; Li Y; Li Z; Che X; Fan Y; Wang S; Qu J; Yang X; Hou K; Zhou W; Xu L; Li C; Wang J; Liu J; Chen L; Zhang J; Qu X; Liu Y
Cancer Immunol Res; 2017 Jul; 5(7):524-534. PubMed ID: 28619967
[TBL] [Abstract] [Full Text] [Related]
